Nasdaq · Healthcare

4D Molecular Therapeutics, Inc. (FDMT)

As-reported financials and recent SEC filings for 4D Molecular Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$85.2M

Net income

$-140.1M

Net margin

—

Diluted EPS

$-2.42

ROE

-27.7%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$85.2M	$37,000	$20.7M	$3.1M	$18.0M
Gross profit	—	—	—	—	—
Operating income	$-159.5M	$-187.8M	$-112.9M	$-110.0M	$-71.3M
Net income	$-140.1M	$-160.9M	$-100.8M	$-107.5M	$-71.3M
Diluted EPS	$-2.42	$-2.98	$-2.58	$-3.32	$-2.57

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

1442026-06-30

8-K2026-06-29

42026-06-25

1442026-06-23

42026-06-23

1442026-06-22

8-K2026-06-22

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on FDMT

Search 4D Molecular Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.